Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Tuberculosis Treatment Drugs Market to Reach $3.2 Billion, Globally, by 2031 at 5.3% CAGR: Allied Market Research

This image opens in the lightbox

News provided by

Allied Market Research

14 Apr, 2023, 08:26 GMT

Share this article

Share toX

Share this article

Share toX

Rising investments in R&D and clinical trials to develop new drugs & treatments for treating tuberculosis and rise in adoption of combinational therapy drive the growth of the global tuberculosis treatment drugs market

PORTLAND, Ore., April 14, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Tuberculosis Treatment Drugs Market by Disease Type (Active TB, Latent TB), by Therapy (First-Line Therapy, Second-Line Therapy), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2022–2031". According to the report, the global tuberculosis treatment drugs industry generated $1.9 billion in 2021, and is anticipated to generate $3.2 billion by 2031, witnessing a CAGR of 5.3% from 2022 to 2031.

Download Free Sample Report: https://www.alliedmarketresearch.com/request-sample/13607

Prime determinants of growth

Rising investments in R&D and clinical trials to develop new drugs & treatments for treating tuberculosis and rise in adoption of combinational therapy drive the growth of the global tuberculosis treatment drugs market. However, stringent regulatory guidelines for product approval and side effects associated with anti-TB drugs restrict the tuberculosis treatment drugs market growth. On the contrary, the growing initiatives from government organizations for tuberculosis awareness are expected to offer remunerative opportunities for expansion of the tuberculosis treatment drugs market during the forecast period.

Covid-19 Scenario

  • The outbreak of the Covid-19 pandemic had a positive impact on the global POU water purifier market, owing to the rise in number of patients suffering from TB and COVID-19 infection.
  • In addition, rise in number of patients affected by drug-resistant tuberculosis and increase in diagnosis and treatment of tuberculosis is expected to contribute to the growth of the market during the forecast period.

The active tuberculosis segment to maintain its leadership status throughout the forecast period

Based on disease type, the active tuberculosis segment held the largest share in 2021, accounting for more than four-fifths of the global tuberculosis treatment drugs market revenue, and is estimated to maintain its leadership status throughout the forecast period, owing to higher prevalence of tuberculosis cases across the globe and rise in number of key players offering novel medications. However, the latent tuberculosis segment is projected to manifest the highest CAGR of 6.6% from 2022 to 2031, owing to increase in prevalence of drug- resistant tuberculosis cases.

The first line therapy segment to maintain its lead position during the forecast period

Based on therapy type, the first line therapy segment accounted for the largest share in 2021, accounting for more than three-fifths of the global tuberculosis treatment drugs market revenue, and is estimated to maintain its leadership status throughout the forecast period, owing to increase in use of these drugs for treating tuberculosis as these drugs are highly effective and used in combination with other antibiotics for treating types of tuberculosis. However, the second line therapy segment is projected to manifest the highest CAGR of 5.9% from 2022 to 2031, owing to increase in prevalence of drug resistance TB in patients.

Procure Complete Report (220 Pages PDF with Insights, Charts, Tables, and Figures) @ https://www.alliedmarketresearch.com/checkout-final/tuberculosis-treatment-drugs-market 

The drug stores and retail pharmacies segment to maintain its lead position during the forecast period

Based on distribution channel, the drug stores and retail pharmacies segment accounted for the largest share in 2021, accounting for nearly half of the global tuberculosis treatment drugs market revenue, and is estimated to maintain its leadership status throughout the forecast period, owing to increase in preference of the people toward retail pharmacies, as retail pharmacies guide regarding medications and usage during treatment period. However, the online providers segment is projected to manifest the highest CAGR of 7.8% from 2022 to 2031, owing to rise in popularity of online pharmacy and number of users preferring online providers.

North America to maintain its dominance by 2031

Based on region, North America held the highest market share in terms of revenue in 2021, accounting for more than one-third of the global tuberculosis treatment drugs market revenue, and is estimated to maintain its leadership status throughout the forecast period, owing to high healthcare awareness along with presence of well-developed healthcare infrastructure, rise in prevalence of tuberculosis infected cases, and ease of drug availability with large number of trained medical professionals. However, the Asia-Pacific region is expected to witness the fastest CAGR of 6.3% from 2022 to 2031, owing to higher prevalence of tuberculosis drug treatment agents, increase in drug resistant TB cases and number of pipeline medications for treating active and latent tuberculosis conditions.

Leading Market Players: -

  • Lupin
  • Macleods Pharmaceuticals Ltd.
  • Sanofi
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Fresenius Se & Co. KAGA (Fresenius Kabi)
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Ani Pharmaceuticals, Inc.

The report provides a detailed analysis of these key players of the global tuberculosis treatment drugs market. These players have adopted different strategies such as acquisition, innovation, joint venture, product launch, agreement, and product approval, to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

Trending Reports in Healthcare Industry (Book Now with 10% Discount):

AI in Healthcare Market by Offering (Software, Hardware, & Services), Algorithm (Deep Learning, Querying Method, Natural Language Processing, and Context Aware Processing), Application (Robot-Assisted Surgery, Virtual Nursing Assistant, Administrative Workflow Assistance, Fraud Detection, Dosage Error Reduction, Clinical Trial Participant Identifier, Preliminary Diagnosis, and Others), and End User (Healthcare Providers, Pharmaceutical & Biotechnology Companies, Patients, and Payer): Global Opportunity Analysis and Industry Forecast, 2021-2030

Biosimilars Market by Type (Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Granulocyte-Colony Stimulating Factor, Others), by Application (Blood disorders, Oncology diseases, Chronic and autoimmune diseases, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Breast Biopsy Market by Product (Vacuum Assisted Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy), by Image Guided Technology (Mri Guided Breast Biopsy, Ultrasound Guided Breast Biopsy, Mammography Guided Stereotactic Biopsy, Ct Guided Biopsy, Other Image Guided Breast Biopsy), by End User (Hospitals And Clinics, Diagnostic Centers): Global Opportunity Analysis and Industry Forecast, 2020-2030

3D Cell Culture Market by Product (Scaffold Based Platforms, Scaffold Free Platforms, Gels, Bioreactors, Microchips, Services), by Application (Cancer Research, Stem Cell Research, Drug Discovery, Regenerative medicine), by End User (Biotechnology and Pharmaceutical Companies, Contract Research Laboratories, Academic Institutes): Global Opportunity Analysis and Industry Forecast, 2021-2031

IVF Devices and Consumables Market by Product (Instruments, Accessories & Disposables, and Reagents & Media), Technology Type (Fresh Embryo IVF, Frozen Embryo IVF, and Donor Egg IVF), and End User (Fertility Clinics, Hospitals, Surgical Centers, and Clinical Research Institutes): Global Opportunity Analysis and Industry Forecast, 2021-2030

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg

Modal title

Also from this source

Blue Light Blocking Glasses Market to Reach $2.9 billion in 2024 in short term and $5,773.4 million by 2034 Globally, at 7.3% CAGR: Allied Market Research

Blue Light Blocking Glasses Market to Reach $2.9 billion in 2024 in short term and $5,773.4 million by 2034 Globally, at 7.3% CAGR: Allied Market Research

Allied Market Research published a report, titled, "Blue Light Blocking Glasses Market Global Opportunity Analysis and Industry Forecast, 2025-2034." ...

Agritech Market to Reach $8,150.15 million by 2024 in the short term and $34,831.17 Million by 2034 Globally, at 15.3% CAGR: Allied Market Research

Agritech Market to Reach $8,150.15 million by 2024 in the short term and $34,831.17 Million by 2034 Globally, at 15.3% CAGR: Allied Market Research

Allied Market Research published a report titled, "Agritech Market - Global Opportunity Analysis and Industry Forecast, 2024-2034", valued at...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.